碳青霉烯类药物L-749,345与其他抗菌药物对多重耐药革兰氏阴性临床病原体的体外活性比较
Comparative in vitro activities of carbapenem L-749,345 and other antimicrobials against multiresistant gram-negative clinical pathogens.
作者信息
Jacoby G, Han P, Tran J
机构信息
Lahey Hitchcock Clinic, Burlington, Massachusetts 01805, USA.
出版信息
Antimicrob Agents Chemother. 1997 Aug;41(8):1830-1. doi: 10.1128/AAC.41.8.1830.
Abstract
Carbapenems L-749,345 and imipenem had the lowest MICs at which 90% of isolates were inhibited (0.5 microg/ml) of 14 antimicrobial agents tested against 76 multiresistant gram-negative clinical isolates with TEM- or SHV-type extended-spectrum beta-lactamases and chromosomal or plasmid-determined AmpC beta-lactamases, but the MIC of L-749,345 for one isolate of Klebsiella pneumoniae was 16 microg/ml.
摘要
碳青霉烯类药物L-749,345和亚胺培南在针对76株具有TEM型或SHV型超广谱β-内酰胺酶以及染色体或质粒介导的AmpCβ-内酰胺酶的多重耐药革兰氏阴性临床分离株测试的14种抗菌药物中，对90%分离株产生抑制作用的最低MIC（最低抑菌浓度）值最低（0.5微克/毫升），但L-749,345对一株肺炎克雷伯菌分离株的MIC为16微克/毫升。
相似文献
1
Comparative in vitro activities of carbapenem L-749,345 and other antimicrobials against multiresistant gram-negative clinical pathogens.碳青霉烯类药物L-749,345与其他抗菌药物对多重耐药革兰氏阴性临床病原体的体外活性比较
Antimicrob Agents Chemother. 1997 Aug;41(8):1830-1. doi: 10.1128/AAC.41.8.1830.
2
Comparative activity of doripenem and three other carbapenems tested against Gram-negative bacilli with various beta-lactamase resistance mechanisms.多利培南与其他三种碳青霉烯类药物针对具有不同β-内酰胺酶耐药机制的革兰氏阴性杆菌的比较活性。
Diagn Microbiol Infect Dis. 2005 May;52(1):71-4. doi: 10.1016/j.diagmicrobio.2004.12.008.
3
Carbapenem susceptibilities and non-susceptibility concordance to different carbapenems amongst clinically important Gram-negative bacteria isolated from intensive care units in Taiwan: results from the Surveillance of Multicentre Antimicrobial Resistance in Taiwan (SMART) in 2009.2009 年台湾地区监控多重抗药性细菌计划（SMART）研究：从台湾加护病房分离之临床重要革兰氏阴性杆菌对于不同碳青霉烯类药品之感受性与不感受性之符合情形。
Int J Antimicrob Agents. 2013 May;41(5):457-62. doi: 10.1016/j.ijantimicag.2013.02.001. Epub 2013 Mar 16.
4
Cefiderocol: A Siderophore Cephalosporin with Activity Against Carbapenem-Resistant and Multidrug-Resistant Gram-Negative Bacilli.头孢地尔：一种具有抗碳青霉烯类和多药耐药革兰氏阴性杆菌活性的铁载体头孢菌素。
Drugs. 2019 Feb;79(3):271-289. doi: 10.1007/s40265-019-1055-2.
5
Comparative in vitro activity of carbapenems against major Gram-negative pathogens: results of Asia-Pacific surveillance from the COMPACT II study.比较碳青霉烯类药物对主要革兰氏阴性病原菌的体外活性：来自 COMPACT II 研究的亚太地区监测结果。
Int J Antimicrob Agents. 2012 Apr;39(4):311-6. doi: 10.1016/j.ijantimicag.2012.01.002. Epub 2012 Mar 3.
6
7
Evaluation of the in vitro activity of six broad-spectrum beta-lactam antimicrobial agents tested against over 2,000 clinical isolates from 22 medical centers in Japan. Japan Antimicrobial Resistance Study Group.对六种广谱β-内酰胺抗菌药物针对来自日本22个医疗中心的2000多株临床分离菌的体外活性进行评估。日本抗菌药物耐药性研究组。
Diagn Microbiol Infect Dis. 1999 Jun;34(2):123-34. doi: 10.1016/s0732-8893(99)00019-x.
8
9
Antimicrobial susceptibility and beta-lactamase production of selected gram-negative bacilli from two Croatian hospitals: MYSTIC study results.来自克罗地亚两家医院的部分革兰氏阴性杆菌的药敏性及β-内酰胺酶产生情况：MYSTIC研究结果
J Chemother. 2010 Jun;22(3):147-52. doi: 10.1179/joc.2010.22.3.147.
10
Roles of beta-lactamases and porins in activities of carbapenems and cephalosporins against Klebsiella pneumoniae.β-内酰胺酶和孔蛋白在碳青霉烯类和头孢菌素类药物对肺炎克雷伯菌活性中的作用。
Antimicrob Agents Chemother. 1999 Jul;43(7):1669-73. doi: 10.1128/AAC.43.7.1669.
引用本文的文献
1
Developing an AI-based prediction model for anaphylactic shock from injection drugs using Japanese real-world data and chemical structure-based analysis.利用日本真实世界数据和基于化学结构的分析开发用于注射药物过敏反应的人工智能预测模型。
Daru. 2024 Jun;32(1):253-262. doi: 10.1007/s40199-024-00511-4. Epub 2024 Apr 5.
2
Efficacy and Safety of Cefmetazole for Bacteremia Caused by Extended-Spectrum β-Lactamase-Producing Enterobacterales vs Carbapenems: A Retrospective Study.头孢美唑治疗产超广谱β-内酰胺酶肠杆菌科细菌所致菌血症的疗效及安全性与碳青霉烯类药物的对比：一项回顾性研究
Open Forum Infect Dis. 2023 Oct 7;10(10):ofad502. doi: 10.1093/ofid/ofad502. eCollection 2023 Oct.
3
Clinical Efficacy of Ertapenem for Recurrent Cystitis Caused by Multidrug-Resistant Extended-Spectrum β-Lactamase-Producing Escherichia coli in Female Outpatients.厄他培南治疗女性门诊患者中由产超广谱β-内酰胺酶的多重耐药大肠埃希菌引起的复发性膀胱炎的临床疗效
Korean J Urol. 2014 Apr;55(4):270-5. doi: 10.4111/kju.2014.55.4.270. Epub 2014 Apr 10.
4
5
Pharmacokinetics and tolerability of single-dose intravenous ertapenem in infants, children, and adolescents.单次静脉注射厄他培南在婴儿、儿童和青少年中的药代动力学和耐受性。
Pediatr Infect Dis J. 2010 Dec;29(12):1072-6. doi: 10.1097/INF.0b013e3181e82608.
6
Pharmacokinetics of Linezolid and Ertapenem in experimental parapneumonic pleural effusion.利奈唑胺和厄他培南在实验性脓胸性胸腔积液中的药代动力学。
J Inflamm (Lond). 2010 May 18;7:22. doi: 10.1186/1476-9255-7-22.
7
Ertapenem resistance among extended-spectrum-beta-lactamase-producing Klebsiella pneumoniae isolates.产超广谱β-内酰胺酶肺炎克雷伯菌分离株中的厄他培南耐药性
J Clin Microbiol. 2009 Apr;47(4):969-74. doi: 10.1128/JCM.00651-08. Epub 2009 Feb 11.
8
Ertapenem resistance of Escherichia coli.大肠埃希菌对厄他培南的耐药性
Emerg Infect Dis. 2007 Feb;13(2):315-7. doi: 10.3201/eid1302.060747.
9
Outer membrane protein changes and efflux pump expression together may confer resistance to ertapenem in Enterobacter cloacae.外膜蛋白变化和外排泵表达共同作用可能使阴沟肠杆菌对厄他培南产生耐药性。
Antimicrob Agents Chemother. 2006 Aug;50(8):2833-5. doi: 10.1128/AAC.01591-05.
10
Ertapenem: a review of its use in the treatment of bacterial infections.厄他培南：其在治疗细菌感染中的应用综述
Drugs. 2005;65(15):2151-78. doi: 10.2165/00003495-200565150-00013.
本文引用的文献
1
Detection of extended-spectrum beta-lactamases in clinical isolates of Klebsiella pneumoniae and Escherichia coli.肺炎克雷伯菌和大肠埃希菌临床分离株中广谱β-内酰胺酶的检测
J Clin Microbiol. 1996 Apr;34(4):908-11. doi: 10.1128/jcm.34.4.908-911.1996.
2
A functional classification scheme for beta-lactamases and its correlation with molecular structure.β-内酰胺酶的功能分类方案及其与分子结构的相关性。
Antimicrob Agents Chemother. 1995 Jun;39(6):1211-33. doi: 10.1128/AAC.39.6.1211.
Zotero 插件